To combine artificial intelligence with the development of anti-cancer drugs

According to the review of Massachusetts Institute of Technology Technology, the US Department of Defense has announced that it will work with the bio-pharmaceutical company Borg Health to make use of artificial intelligence technology to carry out new drug research to find treatment programs of invasive breast cancer which existing drugs can't respond to. The research process will involve recombinant proteins such as recombinant human proteins.

The partnership will support the White House Cancer Luna program, which will screen up to 250,000 samples for new biomarkers and biomarkers for early cancer. According to the National Cancer Institute, breast cancer mortality has declined steadily over the past 20 years, but it remains the second killer of cancers of American women.

Under the terms of the agreement, Borg will have access to the US Department of Defense's clinical breast care program library, which houses 13,600 samples of nearly 8,000 healthy and diseased patients.

Borg's researchers will use a centrifuge to process the laboratory samples. Borg has developed an artificial intelligence platform to rapidly screen patient tissue samples for potential drug targets. The researchers first genetically sequenced samples from healthy donors and samples from a variety of breast cancer subtypes to establish genomic information about mutations, proteins and cellular processes present in cancer cells and normal cells. These data will be combined with the patient's known medical history into the artificial intelligence platform to establish different models of healthy and diseased tissue using tens of thousands of data points. The platform's algorithm will eventually find hotspots in the molecular signatures across these models. These hotspots may represent biomarkers or drug targets.

Niven, co-founder, president and chief executive officer of Borg said, "On contrary to conventional drug development process, the new project will start from the data and generate hypothetical drugs through the data. Narayin believes that there are still some subtypes of breast cancer that have not been identified, the new project may help to identify these unknown subtypes and known subtypes of drug targets. The key biomarkers found in the new project can help identify breast cancer by blood tests, which are less invasive than current biopsy procedures. Flarebio offers recombinant proteins of good quality such as recombinant Aplp2 at competitive prices.